by PARP (Poly ADP-ribose Polymerase) inhibitors are a class of anti-cancer drugs that help block DNA repair in cancer cells with specific deficiencies like BRCA1 and BRCA2 mutations. They act by inhibiting the activity of PARP enzymes that normally help cancer cells repair DNA damage. This leaves the cancer cells unable to effectively repair DNA damage from chemotherapy or radiation therapy. The need for personalized medicines in cancer treatment is driving increased adoption of PARP inhibitors which target specific deficiencies in tumor cells.
The global PARP Inhibitor Market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 11 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of PARP inhibitors in oncology treatment is expected to be a major driver for the PARP inhibitor market over the forecast period. PARP inhibitors are gaining recognition as an important class of targeted therapies for certain types of cancers driven by DNA damage repair deficiencies. Clinical research demonstrates that PARP inhibitors can significantly improve outcomes for patients with breast, ovarian and prostate cancers associated with mutations in DNA repair genes. As awareness regarding personalized cancer treatment based on a patient’s genetic profile increases among oncologists as well as patients, the potential patient pool for PARP inhibitors is likely to expand going forward.
SWOT Analysis
Strength: PARP inhibitors have shown strong clinical efficacy in treating cancers with certain defects in DNA damage repair. Their mechanism of targeting DNA repair vulnerabilities in cancer cells allows them to selectively kill those cells.
Weakness: PARP inhibitors are only effective in cancers with certain defects in DNA repair genes like BRCA1 and BRCA2. They show limited efficacy in cancers without those defects. High treatment costs also limit widespread adoption.
Opportunity: Ongoing research is exploring ways to expand the use of PARP inhibitors to wider range of cancers. Combination therapies with other agents also show promise to enhance efficacy. Growing evidence is demonstrating benefits in newer cancer settings.
Threats: Competition from alternative targeted therapies and immunotherapies pose treatment options. Requirement of genetic profiling also limits eligible patient population. Adverse effects and development of resistance also impact long-term use.
Key Takeaways
The Global PARP Inhibitor Market is expected to witness high growth. Rapid progress in understanding DNA damage response and homologous recombination deficiency has facilitated the development and adoption of PARP inhibitors in oncology.
Regional analysis comprises Europe currently dominates the global market due to high acceptance of PARP inhibitors in the UK and Germany. However, the market in North America is expected to grow at a higher CAGR during the forecast period due to increasing research activities, rising demand for targeted therapies and presence of key players in the region.
Key players operating in the PARP inhibitor market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Clovis Oncology, Inc. AstraZeneca’s Lynparza and GlaxoSmithKline’s Zejula are approved for treatment of ovarian cancer and other BRCA-mutated tumors. Pfizer’s Talzenna is also approved to treat later-stage breast cancer. These companies are extensively conducting clinical trials to expand the use of their PARP inhibitors into new cancer types.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
